The Application of a Matched Design to a Cost-Effectiveness Analysis for Antiplatelet Therapy

Antiplatelet agents, aspirin and clopidogrel, are used for preventing cardiovascular events in patients with stroke, transient ischemic attack, acute or chronic coronary artery diseases, or peripheral arterial diseases. Aspirin has long been known to cause gastrointenstinal (GI) side effects and suggested use of proton-pump inhibitor (PPI) in combination, particularly for patients with GI bleeding history. But the use of clopidogrel plus PPIs provides GI benefits, with this treatment; there is an increased the risk of cardiovascular events among patients with a history of GI bleeding. There are two issues which arise from the above clinic situation. First, an observational study is designed to examine the cost-effectiveness for antiplatelet agents for patients with gastrointenstinal bleeding history. Second, we will develop a new methodology of a cost-effectiveness analysis for a matched data to eliminate a greater proportion of systematic differences in this observational study.

Project ID:PF10007-1072
External Project ID:NSC100-2410-H182-014